
    
      The trial is an open-label, multi-center safety trial of epcoritamab. The trial consists of
      two parts: Part 1, dose escalation (phase 1), and Part 2, expansion (phase 2). The expansion
      part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has been
      determined in Part 1.
    
  